Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CHICAGO--(BUSINESS WIRE)--bioTheranostics today announced that a number of studies on its CancerTYPE ID® molecular cancer classifier are being featured at the 2013 American Society of Clinical Oncology (ASCO) annual meeting. Findings from these studies add to the growing body of evidence supporting the clinical utility of CancerTYPE ID, demonstrating its impact on therapeutic decision making, cost-effectiveness and favorable quality of life, and particular utility in limited-tissue specimens. The studies are among 11 clinical trials and economic analyses released during the ASCO meeting that reinforce the clinical utility, prognostic performance, and cost-effectiveness of the company’s molecular diagnostic tests.
Help employers find you! Check out all the jobs and post your resume.
